key: cord-0842925-pje6jd8e
authors: Koutsakos, Marios; Rowntree, Louise C.; Hensen, Luca; Chua, Brendon Y.; van de Sandt, Carolien E.; Habel, Jennifer R.; Zhang, Wuji; Jia, Xiaoxiao; Kedzierski, Lukasz; Ashhurst, Thomas M.; Putri, Givanna H.; Marsh-Wakefield, Felix; Read, Mark N.; Edwards, Davis N.; Clemens, E Bridie; Wong, Chinn Yi; Mordant, Francesca L.; Juno, Jennifer A.; Amanat, Fatima; Audsley, Jennifer; Holmes, Natasha E.; Gordon, Claire L.; Smibert, Olivia C.; Trubiano, Jason A.; Hughes, Carly M.; Catton, Mike; Denholm, Justin T.; Tong, Steven YC.; Doolan, Denise L.; Kotsimbos, Tom C.; Jackson, David C.; Krammer, Florian; Godfrey, Dale I.; Chung, Amy W.; King, Nicholas JC.; Lewin, Sharon R.; Wheatley, Adam K.; Kent, Stephen J.; Subbarao, Kanta; McMahon, James; Thevarajan, Irani; Nguyen, Thi HO.; Cheng, Allen C.; Kedzierska, Katherine
title: Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
date: 2021-02-05
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100208
sha: ad9ccc513c21971479df37b645b20f3d98273e86
doc_id: 842925
cord_uid: pje6jd8e

SARS-CoV-2 causes a spectrum of COVID-19 disease, the immunological basis of which remains ill-defined. We analysed 85 SARS-CoV-2-infected individuals at acute and/or convalescent timepoints, up to 102 days post-symptom onset, quantifying 184 immunological parameters. Acute COVID-19 presented with high levels of IL-6, IL-18 and IL-10 and broad activation marked by upregulation of CD38 on innate and adaptive lymphocytes and myeloid cells. Importantly, activated CXCR3+cTFH1 cells in acute COVID-19 significantly correlate with and predict antibody levels and their avidity at convalescence as well as acute neutralisation activity. Strikingly, intensive care unit (ICU) patients with severe COVID-19 display higher levels of soluble IL-6, IL-6R, IL-18, and hyperactivation of innate, adaptive and myeloid compartments than patients with moderate disease. Our analyses provide a comprehensive map of longitudinal immunological responses in COVID-19 patients and integrate key cellular pathways of complex immune networks underpinning severe COVID-19, providing important insights into potential biomarkers and immunotherapies.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has caused over 101 million infections and 2.18 million deaths worldwide (28 th Jan 2021). Infection with SARS-CoV-2 results in a spectrum of clinical presentations, named Coronavirus Disease 2019 , ranging from asymptomatic to fatal disease. Disease severity has been associated with risk factors including age, gender and pre-existing comorbidities 1, 2 and correlate with immune responses during acute infection. While robust, broad and transient immune responses precede patients' recovery in non-severe cases [3] [4] [5] [6] , severe COVID-19 can be associated with exuberant cytokine responses, hyperactivation of innate immune cells and T cells 4, 6-8 , as well as high titres of SARS-CoV-2-specific antibodies 8 . At convalescence, the majority of individuals have SARS-CoV-2-specific antibodies, B cell and T cell responses [9] [10] [11] [12] [13] . CD4 + T cell responses appear more prominent than CD8 + T cell responses in primary SARS-CoV2 infection 13, 14 .

Our understanding of immune responses to SARS-CoV-2 informed development and clinical evaluation of immunomodulatory therapies, including monoclonal antibodies that target IL-6 signalling pathway and corticosteroids such as dexamethasone 15 . However, results from clinical trials examining the efficacies of current therapeutic approaches are inconsistent 16 . In parallel, global accelerated efforts are focused on the development of safe vaccines against SARS-CoV-2, with the main goal of eliciting neutralising antibodies against the Spike protein 17 . Efforts are needed to understand integrated immune correlates of recovery and protection from COVID-19, and the complexity of innate and adaptive immune perturbations underpinning severe and fatal COVID-19 to inform the rational design of vaccines and identify predictors of protective immunity.

We performed in-depth analyses of broad innate and adaptive immune responses in longitudinal acute and convalescent blood samples from SARS-CoV-2-infected individuals.

Our study revealed integrated innate and adaptive immune dynamics during COVID-19 up to 102 days post disease symptom onset, with circulating T follicular helper (cT FH ) cells strongly correlating with levels of SARS-CoV-2-specific antibodies. We identified IL-18, soluble IL-6 receptor (sIL-6R) and hyperactivated immune responses depicted by high CD38 expression (CD4 + , CD8 + , γδ T cells, innate cells) and HLA-DR expression (NK cells) as correlates of COVID-19 severity, as well as correlations between dysregulation of cytokines and immune hyperactivation, providing important insights into potential biomarkers and immunotherapies.

We recruited 85 PCR-confirmed COVID-19 cases. 33 symptomatic/hospitalised individuals were recruited, including 20 ward patients (4 requiring supplemental oxygen support), 12 ICU patients (8 requiring invasive ventilation; 3 requiring non-invasive oxygen support) and 1 outpatient. 23 donors were longitudinally sampled up to 6 times while in hospital and 13 of the donors were sampled into convalescence, between day (d) 20 and 80 post-symptom onset. Additional 52 COVID-19 recovered individuals were recruited after discharge from hospital (n=9) or after recovering at home (n=43) ( Figure 1A , Tables S1, S2), with 4 being longitudinally sampled twice between d26 and d102 post-symptom onset for immune profiling and serological analyses ( Figure 1B ). Acute samples were obtained either during the hospital stay in hospitalised patients or within 2 weeks post-symptom onset for the nonhospitalised individual (outpatient) ( Figure 1A ; in red). Convalescent samples were obtained either after hospital discharge or at the earliest d26 post-symptom onset for non-hospitalised individuals ( Figure 1A ; in blue). Disease severity was determined according to whether the patients recovered at home (mild disease), hospital ward (moderate disease) or ICU (severe disease). A total of 66 healthy individuals and 11 non-COVID-19 hospitalised patients were assessed as controls. Our study included one ICU patient, #1-088, with a haematological malignancy treated with rituximab medication, thus lacking B cells. As this donor had no detectable SARS-CoV-2 antibodies, only cellular and cytokine data were included in statistical analyses.

To understand dynamics of immune responses to SARS-CoV-2 over time, we analysed blood from acute and convalescent individuals using 3 multi-parameter flow-cytometric panels. The acute group included moderate (ward) and severe (ICU) samples. Using a computational pipeline in the Spectre R package, encompassing the FlowSOM and UMAP algorithms 18 , we identified clusters representing major lymphocyte and myeloid lineages, and their activation phenotype from the first panel; clusters of adaptive B cell and T cell subsets from the second panel; and cytotoxicity profiles of CD8 + and CD4 + T cells from the third panel ( Figure 1C ). UMAP analysis revealed different subsets of B and T helper (T H ) cells according to CD38 and CXCR3, respectively (second panel), and preferentially high expression of granzyme B and perforin on CD8 + effector memory (T EM ) and effector memory CD45RA + (T EMRA ) T cell subsets (third panel) ( Figure 1C ). To assess immune profiles between acute and convalescent COVID-19 samples, we combined our FlowSOM clustered data with data from 14 soluble mediators and plasma RBD-specific IgG, IgM and IgA antibodies to generate a total of 184 immune features. During acute COVID-19 in hospitalised patients, we observed significant changes in immune compositions compared to healthy controls and/or convalescent samples, particularly greater proportion of neutrophils, J o u r n a l P r e -p r o o f neutrophil-to-lymphocyte and neutrophil-to-T cell ratios, higher proportions of activated populations of CD38 + neutrophils, CD38 + eosinophils, CD38 expression on CD14 + and CD16 + monocytes, CD38 + CD56 dim NK cells, CD38 + γδ T cells, antibody-secreting cells (ASCs), PD-1 + ICOS + cT FH cells, CD38 + CD4 + T cells, HLA-DR + CD4 + T cells and higher proportions of T EMRA -like CD27 -CD45RA + , and CD38 + CD8 + T cells ( Figure 1D , Figure S1 , S2). During convalescence, we found higher proportions of T CM CD8 + T cells, NK cells, T CM and T EM CD4 + T cells ( Figures 1D, S1 Figure 1E , Figure S3 , Table S3 ). Strikingly, the tracking pattern of the CD38 activation marker indicated dynamic activation of both innate and adaptive cells peaking within weeks 2-4 of disease onset (Bins 4-6), before declining at later time-bins ( Figure 1E ). These patterns were still apparent when we excluded the ICU patient #1-088, who had continuously high CD38 expression over 4 time-points. Expression of HLA-DR was also dynamic across timepoints, but to a lesser extent. Overall, our analyses revealed differences in immune profiles across the time between acute and convalescent phases, with broad immune activation of innate, adaptive and myeloid cells.

To define the dynamics of innate responses, we compared 14 cytokines/chemokines in moderate and severe acute and convalescent COVID-19 plasma samples over time, in comparison to healthy controls. As IL-6 is a key driver of inflammation in COVID-19, possibly mediating pathology via engaging sIL-6R on cells expressing the gp130 co-receptor 20 , we also measured sIL-6R levels, since the role of sIL-6R in COVID-19 remains unknown.

Inflammatory cytokines IL-6, IL-18 and IL-10 were significantly upregulated in acute samples compared to convalescent samples ( Figures 1F,G, S4A) , consistent with other studies [21] [22] [23] .

The levels of MCP-1, IFNγ and sIL-6R were also higher in acute samples from some patients compared to healthy controls, but these responses were variable ( Figures 1G,   S4A ,B), possibly reflecting grouping of all ward and ICU patients in this analysis.

To complement our computational analysis, we applied manual gating ( Figure S5 ) for immune subsets that contribute to antiviral immunity in COVID-19 and influenza [24] [25] [26] [27] . Manual J o u r n a l P r e -p r o o f gating showed significantly higher activation of immune subsets in acute COVID-19 compared to convalescent and healthy donors ( Figure S6A ). For innate populations, acute samples had significantly higher proportions of activated HLA-DR + NK cells, CD38 + HLA-DR + γδ T cells and higher proportions of effector-like CD27 -CD45RA + γδ T cells but lower levels of non-classical CD16 + monocytes, compared to convalescent and/or healthy donors (Figures 2A,B ,C; S6B,C). The number of monocytes and γδ T cells were comparable between acute and convalescent samples, while NK cell numbers were significantly lower in the acute samples ( Figure S5D ). These highly activated innate cell populations were dynamic, peaking within the first 3-4 weeks and declining thereafter (Figure 2A ,B,C).

We next defined immune populations that underpin induction of humoral and cellular adaptive immunity, B cells, cT FH cells, Th1 CD4 + and CD8 + T cells. We observed significantly higher proportions and numbers of CD38 hi CD27 + ASCs and activated PD- Moreover, activation of cT FH cells by co-expression of PD-1 and ICOS was more attributed to CXCR3 + cT FH -type 1 (cT FH 1) cells than CXCR3 -cT FH 2/17 cells (Figures 2F, S5E ).

Proportions of ASCs increased rapidly and transiently at disease onset, while activated cT FH 1 cells gradually increased, peaking after 3-4 weeks, similar to activated innate cells, with cT FH 1 cell numbers maintained at convalescence ( Figures 2G, S5E ). There was substantial CD38 + HLA-DR + CD8 + and CD4 + T cell activation during the acute phase, as determined by increased proportions and numbers ( Figure S5F ). Both populations peaked earlier within the first 2-3 weeks and declined thereafter for home and ward patients but remained high till week 6-7 for ICU patients ( Figure 2H ). We also observed greater proportions and numbers of activated PD-1 + CD38 + and CXCR3 + CD38 + CD8 + T cells ( Figure   S5F ) and greater proportions of CD27 -CD45RA + T EMRA -like and CD27 -CD45RA -T EM -like CD8 + T cells in acute samples compared to convalescent or healthy controls ( Figure S5G ).

Similarly, greater proportions of CD27 -CD45RA -T EM CD4 + T cells were detected in acute samples ( Figure S5G ).

To define cytotoxic profiles of CD8 + and CD4 + T cells, the expression of granzyme A, B, K, M and perforin was assessed. Activated CD38 + HLA-DR + CD8 + T cells in acute samples expressed higher levels of granzyme A, B and perforin compared to healthy and/or convalescent ( Figure S7A ,B). Additionally, activated CD38 + HLA-DR + CD8 + T cells in acute samples had higher proportions of cells expressing multiple cytotoxic molecules, with the majority of CD38 + HLA-DR + CD8 + T cells expressing 3 or 4 cytotoxic molecules ( Figure 2J ).

Although expression of granzyme B and perforin within CD38 + HLA-DR + CD8 + T cells J o u r n a l P r e -p r o o f significantly decreased at convalescence, interestingly, granzyme K and M were increased ( Figure S7AB ). The overall diversity of cytotoxic molecule expression, measured by the different combinations of molecules simultaneously expressed per cell, also differed at convalescence as compared to acute COVID-19 and healthy individuals ( Figure 2J ).

While modest, activated CD38 + HLA-DR + CD4 + T cells also expressed higher levels of granzyme B in acute samples ( Figures 2J, S7C,D) . Similar patterns were found when expression of granzymes and perforin were analysed according to their T cell differentiation subsets by FlowSOM analysis ( Figure S8E ).

Overall, SARS-CoV-2 infection induced a prototypical antiviral adaptive immune response comprising ASCs, activated cT FH 1 cells, activated T H 1 CD4 + T cells and highly cytotoxic CD8 + T cells that emerged during acute COVID-19 and contracted during convalescence.

As humoral immunity plays a key role in antiviral responses, we analysed antibodies in acute and convalescent samples from 25 COVID-19 patients across multiple time points, by comparing RBD-specific IgG, IgM and IgA antibodies by ELISA 9 with healthy controls ( Figure   3A , Figure S9 ). Antibody levels were significantly higher in acute (log 10 median titre 3.52

IgG, 3.41 IgM, 2.77 IgA) and convalescent COVID-19 samples (log 10 median titre 3.38 IgG, 3.24 IgM, 2.15 IgA) compared to those in healthy, non-exposed individuals (log 10 median titre 1.68 IgG, 2.49 IgM, 2.15 IgA) ( Figure 3B ). While IgG and IgM titres were maintained at similar levels between acute and convalescent samples, IgA titres had significantly decreased by convalescence. Paired analysis confirmed a significant increase in antibody titres from the first sampling following admission to just prior to discharge or convalescent for all 3 isotypes ( Figure 3C ). At the first acute blood collection, 84%, 48% and 68% of individuals seroconverted (log 10 antibody titre>mean+2xSD of healthy individuals) for RBDspecific IgG, IgM and IgA antibodies, respectively ( Figure 3D ). IgG seroconversion rates increased to 88% and 100% at the last acute blood collection and at convalescence, respectively, although IgM and IgA were maintained at similar frequencies ( Figure 3D ).

Additionally, the proportion of individuals with undetectable RBD-specific IgG, IgM or IgA antibodies decreased from 20.8% during the acute phase to 0% at convalescence, with 100% of convalescent donors having at least an IgG response to RBD ( Figure 3E ).

Consistently, the levels of RBD-specific IgG, IgM and IgA antibodies rapidly increased in the first three weeks, with IgG and IgM levels being maintained between d25-102 ( Figure   S7AB ). We observed a trend towards decreased IgA levels from day 25 onward ( Figure 3F ), but only in 3/25 patients. Additionally, we measured Spike-specific antibodies by ELISA and J o u r n a l P r e -p r o o f detected higher IgG, IgM and IgA antibodies against Spike in pooled acute and convalescent COVID-19 samples compared to healthy donors ( Figure 3G ).

To determine neutralising activity of SARS-CoV-2-specific antibodies, a microneutralisation (MN) assay was performed using live SARS-CoV-2 virus infection of Vero cells 11 . Neutralising antibodies were detected at a low frequency in 3/8 acute patients but were more prevalent in 11/13 convalescent samples, the latter being significantly higher than healthy non-exposed and hospitalized non-COVID patient control groups ( Figure 3H ).

Neutralising activity increased from acute to convalescent phase and was still detectable in 3/3 convalescent donors sampled at ~100 days post-symptom onset ( Figure 3I ). Several antibody measurements correlated significantly with each other ( Figure 3JKLM ). When we ranked COVID-19 patients according to the neutralising activity of SARS-CoV-2-specific antibodies, COVID-19 patients with the highest microneutralisation activity had high levels of RBD-specific IgM, IgG and IgA, suggesting that engagement of a broad range of antibody isotypes might lead to improved neutralising activity ( Figure 3L ). Importantly, antibodies against Spike and neutralising antibody titres correlated with RBD-specific IgG, IgM and IgA antibodies ( Figure 3JKM ). for Spike) and MN titers (r s =0.659). We observed no significant correlations between CXCR3 -cT FH 2/17 cells or activated CD4 + T cells not belonging to the CXCR5 + T FH lineage and antibody responses.

To evaluate the potential of immune populations as predictors of the acute antibody response, we performed linear regression of each immune cell population against each antibody measurement and consistently found ASCs and activated cT FH 1 cells, but not other CD4 + T cell subsets, as significant positive predictors of matched RBD-specific, Spikespecific, and MN titers ( Figure 4B ). While in some instances, the correlations with immune populations were strong (e.g. activated cT FH 1 cells and Spike-specific IgM, R 2 =0.73) or modest (e.g. ASC and MNT, R 2 =0.36), they were weak for RBD-specific antibodies (R 2 <0.2).

Activation of non-T FH cells was also a negative predictor of RBD-specific antibodies ( Figure   4B ). We observed that higher ratios of activated cT FH 1 cells to activated cT FH 2/17 cells or activated cT FH 1 cells to activated T H 1 cells were significant positive predictors of matched MN titres (R 2 =0.624; R 2 =0.404) and RBD-specific antibodies for all isotypes, albeit to a lesser extent (R 2 <0.2) ( Figure 4C ).

As our results are based on immune and antibody analyses from longitudinal samples during the acute COVID-19, and are consistent with data in convalescent individuals 11 , we determined whether immune populations measured at the acute phase could potentially act as biomarkers for convalescent antibody responses. We analysed paired longitudinal data from individuals with acute immune and convalescent RBD antibody data (n=14 patients) using the peak value of the immune cell population when more than one acute measurement was available. The levels of activated cT FH Having shown that activated PD-1 + ICOS + cT FH 1 cells correlate with RBD-, Spike-and MN antibody titers (thus magnitude), we asked whether these cT FH 1 cells could also be associated with qualitative features of antibodies. We first measured the avidity of RBDspecific IgG and IgM antibodies using a urea dissociation assay. In paired COVID-19 plasma samples (n=13) obtained >7 days apart, we found a significant increase in IgG and IgM avidity (% of antibody remaining after 6M urea treatment) in the second plasma sample (Figures 4E, S10B). Avidity also increased with time, where RBD-specific IgG antibodies detected within the first week had significantly lower avidity than samples obtained 3 or more weeks later ( Figure S10C ). The proportion of PD-1 + ICOS + cT FH 1 cells at the acute timepoints positively correlated with antibody avidity for RBD IgM (p=0.0058, R 2 =0.589), but not RBD IgG, at convalescence ( Figure 4F ). Thus, activated PD-1 + ICOS + cT FH patrolling CD16 + monocytes (12.8% vs 8.26%) were found in the ICU compared to the ward group. Strikingly, in some ICU patients, levels of hyperactivated CD38 + HLA-DR + CD4 + T cells constituted ∼80% of all blood CD4 + T cells, while up to 50% of all blood CD8 + T cells, NK cells, and γδ T cells were found in some ICU patients ( Figure 5B ), indicating a nonspecific bystander mode of activation. Moreover, immune cell activation was clearly higher in ICU patients as the total numbers for each parent population were comparable between severity groups ( Figure S11 ). Immune clustering further identified significant differences between ICU and ward, including higher levels of CD38 + HLA-DR + neutrophils, eosinophils, NK cells, γδ, CD4 + and CD8 + T cells in ICU samples ( Figure S12 ). We also found significantly higher neutrophil-to-lymphocyte and neutrophil-to-T cell ratios in ICU patients ( Figure S12 ).

Concomitantly, we also observed significantly different levels of IL-6, IL-18 and sIL-6R, ( Figure 5D ). ICU patients had significantly higher levels of IL-18 (ward 238.8 pg/ml, ICU 700.9 pg/ml) and sIL-6R (ward 40.37 ng/ml, ICU 57.9 ng/ml) (Figures 5d, S11C) . and IL-6 (AUROC=0.7) are potentially predictive of ward vs ICU cases ( Figure 5E ).

Longitudinal analyses verified high levels of IL-18, IL-6, and sIL-6R in ICU patients when compared to the ward patients over time, while the ratio of IL-6 to sIL-6R was variable amongst ICU and ward patients ( Figure 5F ). When paired IL-6 and sIL-6R data were analysed, high IL-6 levels in acute COVID-19 did not imply high sIL-6R levels ( Figure 5G,H) . were reported for severe influenza disease and mortalit 30, 31 . Consistent with other 2 , we found that IL-6 negatively correlated with lymphocyte numbers in blood ( Figure 6B Our results suggest that patients should be screened for both IL-6 and sIL-6R prior to the initiation of anti-IL-6R therapy, especially since critically-ill COVID-19 patients receiving anti-IL-6R therapies may be at higher risk of nosocomial infections 44 . Interestingly, the levels of IL-6 correlate with lymphocytopenia in our cohort and others 2 and treatment with anti-sIL-6R therapies can restore lymphocyte numbers. We also found a correlation between sIL-6R and activation of CD8 + , CD4 + and γδ T cells. Since activated T cells are considered a major source of sIL-6R 45 and severe COVID-19 presents with T cell hyperactivation, this may J o u r n a l P r e -p r o o f explain the elevated levels of sIL-6R and support the idea that sIL-6R may be an informative biomarker.

IL-18 was also associated with COVID-19 severity in our analysis and another report 7 . We found a correlation between IL-18 levels and activation of innate NK cells and γδ T cells, as well as CD4 + and CD8 + T cells, consistent with the potential of IL-18/IL-18R signalling to induce bystander activation of innate and adaptive T cells [46] [47] [48] 

We recognise that some of the analyses performed are limited to a relatively small number of patients available. This is particularly relevant to the analysis of ICU samples, the longevity analysis of antibodies as well as the analysis of neutralising titres. Additionally, we could not stratify our cohort based on age groups or the use of immunomodulatory treatments, which should be the focus of the future studies.

James, Effie Mouhtouris and Ana Copaescu for laboratory work and DRASTIC study coordination. The graphical abstract was created with BioRender.com.

The authors declare no competing interests 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Katherine Kedzierska (kkedz@unimelb.edu.au).

This study did not generate new unique reagents.

Data supporting the findings of this study are available without restriction from the Lead Contact, Katherine Kedzierska (kkedz@unimelb.edu.au) upon request. αcode can be downloaded from www.github.com/ghar1821/TrackSOM.

We 

Fresh whole blood was used to measure cell populations, essentially as described 3 Samples were acquired on a BD LSRII Fortessa and analysed using FlowJo v10 software.

Detection of RBD-and Spike-specific antibodies was performed as described 9 

The avidity of RBD-specific IgG and IgM antibodies in plasma samples was measured using urea as the chaotropic agent. Following incubation of plasma at a 1:31.6, 1:100 and 1:316 J o u r n a l P r e -p r o o f dilution on antigen-coated plates for 2 h, 6M of urea was added after washing and incubated for 15 min. Bound antibodies were then detected using respective secondary detection reagents in procedures described above. Antibody avidity is expressed as the percentage of remaining antibody bound to antigen following urea treatment compared to the absence of urea. Data of 1:100 diluted plasma for IgG and 1:316 for IgM are reported in Figure 4E , with the rest of the data presented in Figure S7A . Data from 1:100 and 1:316 diluted plasma were used for linear regression analysis of IgG and IgM avidity respectively in Figure 4F .

Microneutralisation activity of serum samples was assessed as previously described 57 .

SARS-CoV-2 isolate CoV/Australia/VIC01/2020 58 

Computational analysis of data was performed using the Spectre R package 59 (www.github.com/sydneycytometry/spectre). Samples were initially prepared in FlowJo, and populations of interest were exported as CSV files containing scale value (raw) data. In R, data were subject to arcsinh transformation, and data below the limit of detection were compressed to reduce the contribution of noise to the clustering process. Batch alignment was then performed using CytoNorm 60 as implemented in Spectre. Aligned data were then clustered using FlowSOM and a subset of cells plotted using UMAP 61 ChronoClust's tracking mechanism. TrackSOM was using 10x10 grid, producing 40 metaclusters per time. Binned groups are outlined in Table S3 .

Statistical significance was assessed using Mann-Whitney, Wilcoxon signed-rank test or

Kruskal-Wallis test with Dunn's correction for multiple comparisons in Prism 8 (GraphPad) unless stated otherwise. Analysis of immune parameters against days post-onset were visualised in R 3.6.2 using the ggplot2 package 62 using LOESS fitting with 95% confidence J o u r n a l P r e -p r o o f intervals shaded in grey. Correlations were assessed using Spearman's correlation coefficient (r s ) and visualised in R 3.6.2 as circos plots using the circlize package 63 or heatmaps using the corrplot package and p-values of correlations were corrected for multiple comparisons by FDR in R 3.6.2. Cytokine concentrations were log 10 (x+1) transformed for correlation analysis. Linear regression analysis was performed in Prism 8 (GraphPad). AUROC analysis was performed in R 3.6.2 using the pROC and plotROC packages 64 . Pie charts in figure 3 were generated using Pestle v2 and Spice v6 software 65 and p-values were calculated using a Permutation Test. P-values lower than 0.05 were considered statistically significant.

Supplemental information Table S4 . Comparison of 184 immune features between acute and convalescent samples, related to figure 1D .

A race to determine what drives COVID-19 severity

Viral and host factors related to the clinical outcome of COVID-19

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Comprehensive mapping of immune perturbations associated with severe COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Longitudinal analyses reveal immunological misfiring in severe COVID-19

A dynamic COVID-19 immune signature includes associations with poor prognosis

A serological assay to detect SARS-CoV-2 seroconversion in humans

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Suboptimal SARS-CoV-2-specific CD8+ T

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

The conundrum of interleukin-6 blockade in COVID-19

Approaches and Challenges in SARS-CoV-2 Vaccine Development

FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data

ChronoClust: Density-based clustering and cluster tracking in high-dimensional time-series data

Cytokine release syndrome in severe COVID-19

Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease. medRxiv. 22

Is a "Cytokine Storm" Relevant to COVID-19?

Human CD8(+) T cell cross-reactivity across influenza A, B and C viruses

Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity

Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease

Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study

With a Little Help from T Follicular Helper Friends: Humoral Immunity to Influenza Vaccination

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load

Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection

RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection

Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination

Circulating CXCR3(+) Tfh cells positively correlate with neutralizing antibody responses in HCV-infected patients

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRbeta clonotypes

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

The COVID-19 vaccine development landscape

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients

Interleukin-6 Family Cytokines

Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis

IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells

Anti-viral CD8 T cells and the cytokines that they love

Unique Action of Interleukin-18 on T Cells and Other Immune Cells

Type I IFNs and IL-18 regulate the antiviral response of primary human gammadelta T cells against dendritic cells infected with Dengue virus

A Study to Investigate the Efficacy and Safety of an Anti-Interleukin

Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus

Interleukin-18 in Health and Disease

Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point

Unique human immune signature of Ebola virus disease in Guinea

Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees

Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients from India

Roles of CD38 in the Immune Response to Infection. Cells

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia

Analysis of the Murine Bone Marrow Hematopoietic System Using Mass and Flow Cytometry

CytoNorm: A Normalization Algorithm for Cytometry Data

UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction

Elegant Graphics for Data Analysis

circlize Implements and enhances circular visualization in R

plotROC: A Tool for Plotting ROC Curves

SPICE: exploration and analysis of post-cytometric complex multivariate datasets

We thank all the participants in the study; Jeni Mitchell, Robyn Esterbauer, Hannah Kelly, Jane Batten, Helen Kent, Jill Garlick, Janine Roney, Anne Paterson for support with cohorts.